Diabetes

• Antigen-Based Therapy for the Treatment of Type 1 Diabetes The use of ABTs for autoimmune disease is still in its infancy, but recent results from clinical studies hold promise that this approach may be able to delay the onset of type 1 diabetes.
  Diabetes, November 2009
• Adult Stature and Diabetes Complications in Patients With Type 1 Diabetes: The FinnDiane Study and the Diabetes Control and Complications Trial What is the correlation between height and the development of microvascular complications in patients with Type 1 diabetes?
  Diabetes, November 2009
• Mortality and Glycemic Targets in the Intensive Care Unit: Another Paradigm Shift? Hospitals and clinicians should avoid a knee jerk reaction to the findings of the NICE-SUGAR trial.
  Diabetes, July 2009
• Abnormal Angiogenesis in Diabetic Nephropathy Novel therapies that target angiogenic pathways, such as the angiopoietin and Notch families, could be an attractive option to block diabetic nephropathy in the future.
  Diabetes, July 2009
• Attenuated Sympathoadrenal Responses, but Not Severe Hypoglycemia, During Aggressive Glycemic Therapy of Early Type 2 Diabetes Iatrogenic hypoglycemia is a major limiting factor in the strict glycemic management of diabetes.
  Diabetes, March 2009
• Effects of Intensive Therapy and Antecedent Hypoglycemia on Counterregulatory Responses to Hypoglycemia in Type 2 Diabetes Intensive oral combination therapy and antecedent hypoglycemia both blunt physiological defenses against subsequent hypoglycemia in type 2 diabetes.
  Diabetes, March 2009
• Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: Associations With Neonatal Anthropometrics Is there a continuous relationship between maternal glycemia and neonatal adiposity?
  Diabetes, February 2009
• Somatostatin Secreted by Islet delta-Cells Fulfills Multiple Roles as a Paracrine Regulator of Islet Function What is somatostatin's role in controlling the release of glucagon?
  Diabetes, February 2009
• Can We Learn From Viruses How to Prevent Type 1 Diabetes? What is the role of viral infections in the pathogenesis of type 1 diabetes, and the development of novel combination therapies?
  Diabetes, January 2009
• Follow-Up Analysis of Genome-Wide Association Data Identifies Novel Loci for Type 1 Diabetes Two recent genome-wide association studies have revealed novel loci for type 1 diabetes, a common multifactorial disease with a strong genetic component.
  Diabetes, January 2009
• Ghrelin Infusion in Humans Induces Acute Insulin Resistance and Lipolysis Independent of Growth Hormone Signaling The direct effects of ghrelin on substrate metabolism and insulin sensitivity was the subject of this study.
  Diabetes, December 2008
• Diabetes, Abdominal Adiposity, and Atherogenic Dyslipoproteinemia in Women Compared With Men Why does atherogenic risk differ more between diabetic and nondiabetic women than between diabetic and nondiabetic men?
  Diabetes, December 2008
• Viral Trigger for Type 1 Diabetes: Pros and Cons This article discusses epidemiological and experimental evidence for the main mechanisms accounting for the role of viruses in type 1 diabetes.
  Diabetes, November 2008
• Primer: Immunity and Autoimmunity This review introduces current immune concepts specifically relevant to type 1 diabetes.
  Diabetes, November 2008
• Exendin-4 Stimulation of Cyclin A2 in B-Cell Proliferation B-cell proliferation is an important mechanism underlying B-cell mass adaptation to metabolic demands. The authors examine effects of the incretin hormone analog exendin-4 on cell cycle regulation in B-cells.
  Diabetes, October 2008
• Extension of Type 2 Diabetes Genome-Wide Association Scan Results in the Diabetes Prevention Program Genome-wide association scans have identified novel diabetes-associated genes. We evaluated how these variants impact diabetes incidence, quantitative glycemic traits, and response to preventive intervention.
  Diabetes, September 2008
• Pioglitazone Decreases Fasting and Postprandial Endogenous Glucose Production in Proportion to Decrease in Hepatic Triglyceride Content Hepatic triglyceride is closely associated with hepatic insulin resistance, and is known to be decreased by thiazolididinediones. What is the effect of pioglitazone on hepatic triglyceride content, and the consequent effect on postprandial EGP in type 2 diabetes?
  Diabetes, September 2008
• Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes Activation of the receptor for advanced glycation end products in diabetic vasculature is considered to be a key mediator of atherogenesis.
  Diabetes, September 2008
• Relationship of Abdominal Visceral and Subcutaneous Adipose Tissue With Lipoprotein Particle Number and Size in Type 2 Diabetes Insulin resistance and type 2 diabetes are associated with an atherogenic lipoprotein profile. We examined the role of visceral and subcutaneous fat depots, independent of BMI, on the dyslipidemia associated with type 2 diabetes.
  Diabetes, August 2008
• Association Analysis in African Americans of European-Derived Type 2 Diabetes Single Nucleotide Polymorphisms From Whole-Genome Association Studies Several whole-genome association studies have reported identification of type 2 diabetes susceptibility genes in various European-derived study populations. Little investigation of these loci has been reported in other ethnic groups, specifically African Americans.
  Diabetes, August 2008